Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

29.45 +0.09 (+0.31%)

Official Closing Price Updated: 7:00 PM EST, Nov 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs ↗

October 21, 2026

Biotech and pharma stocks, tracked by the iShares Biotechnology ETF, have shown relative strength amid the tech sell-off, with Eli Lilly and Pfizer standing out as top performers.

Via MarketBeat

Topics Artificial Intelligence ETFs

Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice ↗

October 21, 2026

This company made headlines with its coronavirus vaccine.

Via The Motley Fool

A Look Back at Generic Pharmaceuticals Stocks’ Q2 Earnings: Viatris (NASDAQ:VTRS) Vs The Rest Of The Pack

October 20, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how generic pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Most Active S&P 500 Stocks in Today's Session ↗

October 20, 2026

Via Chartmill

Topics Stocks

Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally? ↗

October 19, 2026

The stock has outperformed the market this year, and it still looks heavily undervalued.

Via The Motley Fool

Topics Artificial Intelligence

Another BioNTech Cancer Vaccine Just Hit a Major Setback. Is BNTX Stock Still a Buy? ↗

October 18, 2026

It has been a volatile year for the biotech.

Via The Motley Fool

Warren Buffett's Market Warning Is Hard to Ignore. But I'd Buy These 3 Stocks Anyway. ↗

October 18, 2026

Not every company is at risk.

Via The Motley Fool

Topics Economy Intellectual Property

Here's What $10,000 in Each of These 5 High-Yield Dividend Stocks Could Pay You in a Year ↗

October 18, 2026

These five high-yield dividend stocks are paying yields of 5.88% to 16.72% -- but beware of a few key risks.

Via The Motley Fool

Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? ↗

October 17, 2026

The gene-editing biotech stock is down more than 12% this year.

Via The Motley Fool

Topics ETFs Lawsuit

Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline ↗

October 17, 2026

BioNTech has billions in cash, and its oncology programs are moving into late-stage clinical trials.

Via The Motley Fool

Here's How Many Shares of AbbVie You'd Need for $5,000 in Yearly Dividends ↗

October 16, 2026

You'd need to invest over $200,000 in the pharma leader at its current price.

Via The Motley Fool

Topics Intellectual Property

Pfizer Just Declared Its 352nd Straight Quarterly Dividend. Is the 6% Yield Safe? ↗

October 16, 2026

Pfizer's dividend yield is attractive, but investors need to know if it can maintain it.

Via The Motley Fool

Topics Intellectual Property

Most-Active S&P 500 Stocks in Oct. 16, 2026 US Session ↗

October 16, 2026

Via Chartmill

Topics Stocks

6 Blue Chip Stocks Trading Well Below Their Highs ↗

October 16, 2026

Some look like bargains, but others could be value traps.

Via The Motley Fool

2 High-Yield Dividend Stocks Worth Buying Before 2026 Ends ↗

October 15, 2026

Verizon and Pfizer pay generous dividends, and each has a different path to growth. Here's how income investors can lock in yield before year-end.

Via The Motley Fool

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 15, 2026

AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.

Via The Motley Fool

Topics Intellectual Property

Most active S&P500 stocks in Wednesday's session ↗

October 14, 2026

Via Chartmill

Exploring the top movers within the S&P500 index during today's session. ↗

October 14, 2026

Via Chartmill

Forget Treasury Bonds: This 6%-Yielding Pharma Stock Pays You to Wait for Its Pipeline ↗

October 14, 2026

A reliable payout, a growing cancer treatment lineup, and improving guidance make this drugmaker worth a second look right now.

Via The Motley Fool

Topics Bonds

Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026

October 14, 2026

From Pfizer Inc.

Via Business Wire

Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers

October 12, 2026

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 12, 2026

Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.

Via The Motley Fool

Topics Intellectual Property

Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens ↗

October 11, 2026

PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.

Via The Motley Fool

Topics ETFs

How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? ↗

October 10, 2026

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.

Via The Motley Fool

Topics Intellectual Property

Better Pharma ETF: iShares IHE vs. State Street XPH ↗

October 10, 2026

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.

Via The Motley Fool

Topics ETFs

Alnylam vs. Ionis: Here's the Better Bad-News Buy ↗

October 10, 2026

The sell-offs for both of these beaten-down biotech stocks appear to be overdone.

Via The Motley Fool

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 08, 2026

Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.

Via The Motley Fool

Topics Intellectual Property

2 Growth Stocks to Buy in October ↗

October 08, 2026

Grail and Veeva Systems could be well insulated from near-term headwinds.

Via The Motley Fool

Pfizer Trades Under 10 Times Forward Earnings With a Yield Near 6%. Here's What History Says Happens Next. ↗

October 08, 2026

Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet.

Via The Motley Fool

Topics Intellectual Property

Avident Health and Unite for HER Awarded Quality Improvement Grant from Pfizer and the National Comprehensive Cancer Network® (NCCN®) to Support Metastatic Breast Cancer Patients

October 08, 2026

October 8, 2026 -- Initiative leverages the MyNavigator™ digital care coordination platform to translate NCCN Guidelines® into actionable home-based education, expand access to integrative oncology...

Via 24-7 Press Release

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.